Biology subjects

Wheeler, M. B.

Publications and source records attributed to Wheeler, M. B..

5 recordsLinked to original sources

bioRxiv2026

Single Cell Mapping Identifies CD14+ Macrophages as Central Orchestrators of CD8+ T Cell Driven Immune Niches in clinical Type 1 diabetes

The authors have withdrawn this manuscript after identifying an error in the annotation of donor disease status in one or more datasets used in the study. The error arose from inadequate or ambiguous disease-status labeling in the corresponding GEO dataset at NCBI. The authors personally communicated with the dataset depositor to verify the disease status of the relevant samples. Subsequent verification indicated that the deposited metadata required correction to accurately reflect the disease status of these samples, which may affect the results and interpretation of the study. The authors therefore took the initiative to work with the GEO/NCBI database administrators to correct the relevant sample annotations and are currently reassessing the analyses using the corrected metadata. The authors believe that withdrawal of the current version is appropriate until this reassessment is complete and a revised version can be prepared. This withdrawn version should not be cited or relied upon as a reference until a revised version is made available. Any questions regarding the withdrawal or ongoing reassessment should be directed to the corresponding author.

pathology↗

bioRxiv2022

metGWAS 1.0: An R workflow for network-driven over-representation analysis between independent metabolomic and meta-genome wide association studies

BackgroundMany diseases may result from disrupted metabolic regulation. Metabolite-GWAS studies assess the association of polymorphic variants with metabolite levels in body fluids. While these studies are successful, they have a high cost and technical expertise burden due to combining the analytical biochemistry of metabolomics with the computational genetics of GWAS. Currently, there are 100s of standalone metabolomics and GWAS studies related to similar diseases or phenotypes. A method that could statically evaluate these independent studies to find novel metabolites-genes association is of high interest. Although such an analysis is limited to genes with known metabolite interactions due to the unpaired nature of the data sets, any discovered associations may represent biomarkers and druggable targets for treatment and prevention. MethodsWe developed a bioinformatics tool, metGWAS 1.0, that generates and statistically compares metabolic and genomic gene sets using a hypergeometric test. Metabolic gene sets are generated by mapping disease-associated metabolites to interacting proteins (genes) via online databases. Genomic gene sets are identified from a network representation of the GWAS Catalog comprising 100s of studies. ResultsThe metGWAS 1.0 tool was evaluated using standalone metabolomics datasets extracted from two metabolomics-GWAS case studies. In case-study 1, a cardiovascular disease association study, we identified nine genes (APOA5, PLA2G5, PLA2G2D, PLA2G2E, PLA2G2F, LRAT, PLA2G2A, PLB1, and PLA2G7) that interact with metabolites in the KEGG glycerophospholipid metabolism pathway and contain polymorphic variants associated with cardiovascular disease (P < 0.005). The gene APOA5 was matched from the original metabolomics-GWAS study. In case study 2, a urine metabolome study of kidney metabolism in healthy subjects, we found marginal significance (P = 0.10 and P = 0.13) for glycine, serine, and threonine metabolism and alanine, aspartate, and glutamate metabolism pathways to GWAS data relating to kidney disease. ConclusionThe metGWAS 1.0 platform provides insight into developing methods that bridge standalone metabolomics and disease and phenotype GWAS data. We show the potential to reproduce findings of paired metabolomics-GWAS data and provide novel associations of gene variation and metabolite expression.

bioinformatics↗

bioRxiv2022

Design of an islet-on-a-chip device reveals glucose-stimulated respiration is substrate limited by glycolytic flux through PKM2

Pancreatic islets respond metabolically to glucose by closing KATP channels resulting in Ca2+-influx and insulin secretion. Previous work has revealed the importance of glycolytic flux in triggering insulin secretion. However, it is unclear whether the triggered ( first phase) secretion is further amplified by Ca2+-stimulation of mitochondrial NADH production and/or oxidative phosphorylation (OxPhos). Although commercially available tools have been developed to explore islet metabolism, these methods often overlook islet variability and have poor spatiotemporal resolution. To tease apart first phase glucose-stimulated respiration, we designed an islet-on-a-chip microfluidic device to simultaneously measure O2-consumption rate (OCR) and Ca2+-activity of individual islets with high temporal resolution. We used finite element analysis to optimize placement of sensor in optically clear microwells on a thin glass coverslip. The microfluidic channels were subsequently fabricated using O2-impermeable plastic to limit outside-in diffusion and push islets against the microsensor. We validated our device using living mouse islets and well-established modulators of respiration. By inhibiting glycolysis and mitochondrial pyruvate transport, we show that islet OxPhos is limited by NADH-substrate rather than ADP in low and high glucose. We subsequently imaged glucose-stimulated OCR and Ca2+-influx simultaneously to reveal a biphasic respiratory response that is determined by glycolytic flux through pyruvate kinase (PKM2) and independent of Ca2+. These data demonstrate the unique utility of our modular and optically clear O2-sensor to simultaneously measure glucose-stimulated OCR and Ca2+ activity of multiple individual islets.

bioengineering↗

bioRxiv2021

Repair of critical-size porcine craniofacial bone defects using a collagen-polycaprolactone composite biomaterial

Regenerative medicine approaches for massive craniomaxillofacial bone defects face challenges associated with the scale of missing bone, the need for rapid graft-defect integration, and challenges related to inflammation and infection. Mineralized collagen scaffolds have been shown to promote mesenchymal stem cell osteogenesis due to their porous nature and material properties, but are mechanically weak, limiting surgical practicality. Previously, these scaffolds were combined with 3D-printed polycaprolactone mesh to form a scaffold-mesh composite to increase strength and promote bone formation in sub-critical sized porcine ramus defects. Here, we compare the performance of mineralized collagen-polycaprolactone composites to the polycaprolactone mesh in a critical-sized porcine ramus defect model. While there were no differences in overall healing response between groups, our data demonstrated broadly variable metrics of healing regarding new bone infiltration and fibrous tissue formation. Abscesses were present surrounding some implants and polycaprolactone polymer was still present after 9-10 months of implantation. Overall, while there was limited successful healing, with 2 of 22 implants showed substantial levels of bone regeneration, and others demonstrating some form of new bone formation, the results suggest targeted improvements to improve repair of large animal models to more accurately represent craniomaxillofacial bone healing. Notably, strategies to increase osteogenesis throughout the implant, modulate the immune system to support repair, and employ shape-fitting tactics to avoid implant micromotion and resultant fibrosis. Improvements to the mineralized collagen scaffolds involve changes in pore size and shape to increase cell migration and osteogenesis and inclusion or delivery of factors to aid vascular ingrowth and bone regeneration.

bioengineering↗

bioRxiv2020

Nicotinamide promotes differentiation of pancreatic endocrine progenitors from human pluripotent stem cells through poly (ADP-ribose) polymerase inhibition

The generation of pancreatic endocrine progenitor cells is an important step in the differentiation of beta cells from human pluripotent stem cells (hPSC). This stage is marked by the expression of Nkx6.1, a transcription factor with well understood downstream targets but with unclear upstream regulators. In hPSC differentiation, Nkx6.1 is strongly induced by nicotinamide, a derivative of vitamin B3, which has three known functions within a cell. Nicotinamide inhibits two classes of enzymes known as poly-ADP-ribose polymerases (PARPs) and sirtuins. It also contributes to the cellular pool of nicotinamide adenosine deoxynucleotide (NAD+) after conversion in the nicotinamide salvage pathway. Induction of Nkx6.1 expression in pancreatic endocrine progenitors by nicotinamide was mimicked by 3 PARP inhibitors (PJ34, olaparib, NU1025). Small molecule inhibition of the nicotinamide salvage pathway reduced Nkx6.1 expression but not Pdx1 expression and caused alteration in NAD+/NADH ratio. Nkx6.1 expression was not affected by sirtuin inhibition. Metabolic profiling of differentiating pancreatic and endocrine progenitors showed that oxygen consumption increases as differentiation progresses, and that nicotinamide reduces oxygen consumption rate. Expression of Nkx6.1 and other beta cell related genes, including Ins2 and Pdx1 increased in mouse islets after exposure to nicotinamide. In summary, nicotinamide induced Nkx6.1 expression in differentiating human pancreatic endocrine progenitors through inhibition of the PARP family of enzymes. Nicotinamide administration was also associated with increased NAD+/NADH ratio, without affecting Nkx6.1 expression. Similarly, the association between nicotinamide and Nkx6.1 expression was also seen in isolated mouse islets. These observations show a link between the regulation of beta cell identity and the effectors of NAD+ metabolism, suggesting possible therapeutic targets in the field of diabetes.

developmental biology↗